Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease.

Medicina (Kaunas) · 2023 · PMC10608225 · PMID 37893507

Europe PMC DOI

hedged sentences

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

marginally significantp = 0.05actually significant

In a phase I clinical trial, the FASN inhibitor (TVB-2640) effectively reduced de novo lipogenesis in the liver, which was accompanied by a marginally significant ALT reduction (15.8 ± 8.4%; p = 0.05) [ 136 ].

also in 26,082 other papers

showed a trendno p-value reported

Those results were somewhat unexpected, while the previous results showed a trend toward reduced lipid accumulation in the liver during fibrate therapy.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.